Coraopolis, PA, United States of America

Nick Giannoukakis

This inventor holds 9 USPTO granted patents and 3 published patent applications, plus 5 CIPO patents and 5 EPO patents. Top assignees: University of Pittsburgh, Baxter International Inc., Baxter Healthcare Sa. Active years: 2005-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nick Giannoukakis. Retrieved from https://idiyas.com/inventor/nick-giannoukakis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 3)

% Patents Active = 66.7

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 2.8

ph-index = 4

Forward Citations = 37(Granted Patents)

Location History:

Pittsburgh, PA (US) (2005)
Coraopolis, PA (US) (2011 - 2021)

Company Filing History:

9 out of 1,960

University of Pittsburgh

patents

4 out of 2,533

Baxter International Inc.

where one patent can have more than one assignee

Years Active: 2005-2021

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10940164 - Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies (2021-03-09),

2. 10272112 - Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies (2019-04-30),

3. 10105334 - Particle formulations of all-trans retinoic acid and transforming growth factor beta for the treatment of type 1 diabetes mellitus (2018-10-23),

4. 9724365 - Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies (2017-08-08),

5. 9115357 - Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes (2015-08-25),

6. 8389493 - Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes (2013-03-05),

7. 8022046 - Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes (2011-09-20),

8. 7964574 - Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes (2011-06-21),

9. 6936468 - Use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same (2005-08-30),

Title: Innovations by Nick Giannoukakis: Pioneering Autoimmune Therapies

Introduction

Nick Giannoukakis is a distinguished inventor based in Coraopolis, PA, who has contributed significantly to the field of autoimmune therapies. With a total of nine patents to his name, Giannoukakis has demonstrated a strong commitment to advancing medical science through his inventive solutions.

Latest Patents

One of his latest patents focuses on "Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies." This innovative invention relates to the development of tolerogenic mammalian dendritic cells (iDCs) and outlines methods for producing these crucial cells. Furthermore, the patent provides techniques for the administration of tolerogenic dendritic cells, along with particles containing oligonucleotides, to mammalian subjects. The enhanced tolerogenicity in a host can be particularly useful for treating inflammatory and autoimmune-related diseases, such as type 1 diabetes.

Career Highlights

Throughout his career, Giannoukakis has made notable contributions while working with prominent organizations, such as the University of Pittsburgh and Baxter International Inc. His work has not only advanced scientific understanding but has also opened new avenues for effective treatments in autoimmune disease management.

Collaborations

Giannoukakis has collaborated with esteemed colleagues, including Massimo M. Trucco and Larry Richard Brown. These partnerships have further enriched his research and invention pursuits, leading to innovative developments that improve patient outcomes in the realm of autoimmune therapies.

Conclusion

Nick Giannoukakis stands out as a prominent inventor in the field of autoimmune therapy research. His innovative patents and collaborations demonstrate a relentless pursuit of knowledge and advancement in medical technology. As he continues to develop groundbreaking solutions, his work promises to have a lasting impact on the treatment of autoimmune diseases.

Profile summary based on public USPTO records.